307
Views
2
CrossRef citations to date
0
Altmetric
Original research

The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancer

& ORCID Icon
Pages 497-504 | Received 01 Dec 2020, Accepted 25 Feb 2021, Published online: 08 Apr 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Akina Takami, Masafumi Kato, Hisato Deguchi & Ataru Igarashi. (2023) Value elements and methods of value-based pricing for drugs in Japan: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 23:7, pages 749-759.
Read now

Articles from other publishers (1)

Wei Fang Dai, Jaclyn M. Beca, Chenthila Nagamuthu, Ning Liu, Claire de Oliveira, Craig C. Earle, Maureen Trudeau & Kelvin K. W. Chan. (2022) Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer. JAMA Oncology 8:4, pages 597.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.